• Fresenius Group 
    • To our Shareholders 
    • Summary of the Fiscal Year 
    • Fresenius Shares 
    • Business Segments 
      • Fresenius Medical Care 
      • Fresenius Kabi 
      • Fresenius Helios 
      • Fresenius Vamed 
    • Additional Group Information 
      • Employees 
      • Research and Development 
      • Environmental Management 
      • Financial Calendar 
  • Transparency & Governance 
    • Report of the Supervisory Board 
    • Corporate Governance Report 
    • Committees 
      • Management Board 
      • Supervisory Board 
  • Management Report 
    • Operations and Business Environment 
      • Group Structure and Business 
      • Corporate Performance Criteria, Goals and Strategy 
      • Research and Development 
      • Overall Business Development 
    • Results of Operations, Financial Position, Assets and Liabilities 
      • Results of Operations 
      • Financial Position 
      • Assets and Liabilities 
    • Non-Financial Performance Indicators and other Success Factors 
      • Employees 
      • Procurement 
      • Quality Management 
      • Sales, Marketing and Logistics 
    • Overall Assessment of the Business Situation 
    • Opportunities and Risk Report 
      • Opportunities Management 
      • Risk Management 
      • Risk Areas 
      • Assessment of Overall Risk 
      • Corporate Rating 
    • Subsequent Events 
    • Outlook 
      • General and Mid-Term Outlook 
      • Future Markets 
      • Economic Outlook 
      • Health Care Sector and Markets 
      • Group Sales and Group Earnings 
      • Sales and Earnings by Business Segment 
      • Financing 
      • Investments 
      • Procurement 
      • Research and Development 
      • Corporate Legal Structure and Organization 
      • Planned Changes in Human Resources and the Social Area 
      • Dividend 
    • Key Figures of Major Affiliated Companies 
  • Consolidated Financial Statements 
    • Auditor`s Report 
    • Consolidated Statement of Income 
    • Consolidated Balance Sheet 
    • Consolidated Cash Flow Statement 
    • Consolidated Statement of Shareholders´ Equity 
    • Segment Reporting 
    • Notes 
      • 1. Principles 
      • 2. Acquisitions and divestitures 
      • 3. Sale 
      • 4. Cost of sales 
      • 5. Cost of materials  
      • 6. Personnel expenses 
      • 7. Selling, general and administrative expenses 
      • 8. Net interest 
      • 9. Taxes 
      • 10. Earnings per share 
      • 11. Cash and cash equivalents  
      • 12. Trade accounts receivable 
      • 13. Inventories 
      • 14. Prepaid expenses and other current and non-current assets 
      • 15. Property, plant and equipment 
      • 16. Goodwill and other intangible assets 
      • 17. Other accrued expenses 
      • 18. Other liabilities  
      • 19. Debt and liabilities from capital lease obligations 
      • 20. Senior Notes 
      • 21. Pensions and similar obligations 
      • 22. Trust preferred securities  
      • 23. Minority interest  
      • 24. Shareholders’ equity  
      • 25. Other comprehensive income (loss) 
      • 26. Commitments and contingent liabilities 
      • 27. Financial instruments  
      • 28. Supplementary information on capital management 
      • 29. Supplementary information on cash flow statement  
      • 30. Notes on segment reporting  
      • 31. Stock options 
      • 32. Related party transactions  
      • 33. Subsequent events  
      • 32. Related party transactions 
      • 33. Subsequent events 
      • 34. Compensation report 
      • 35. Information on the Supervisory Board 
      • 36. D&O Insurance 
      • 37. Auditor’s fees 
      • 38. Corporate Governance 
      • 39. Proposal for the distribution of earnings 
      • 40. Responsibility statement 
  • Portal 
  • vergrößern
  • verkleinern
  • Fontsize
  • Downloadcenter
  • Personal Report
  • Deutsch
  • Glossary
  • Sitemap
  • Disclaimer
  • Contact
  • Home

Fresenius Medical Care
 

Fresenius KABI

Fresenius HELIOS


Fresenius VAMED


More than 1.6 million patients worldwide regularly receive dialysis treatment. Using our holistic approach, we are moving forward to improve dialysis therapy.
More than 40% of all cancer patients are malnourished.* Clinical nutrition can enhance the success of a therapy and improve a patient’s quality of life.
About 200,000 people suffer from stroke each year in Germany alone. Timely diagnosis and advanced therapies help to save lives.
The hospital of the future will be an interprofessional and interdisciplinary health care center focused on patient processes already at the planning stage.